Integra LifeSciences (IART) Expected to Post Earnings on Wednesday

Integra LifeSciences (NASDAQ:IART) is expected to release its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect Integra LifeSciences to post earnings of $0.48 per share and revenue of $417.6170 million for the quarter. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Investors may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:30 AM ET.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The company had revenue of $391.92 million during the quarter, compared to the consensus estimate of $381.81 million. During the same quarter last year, the company earned $0.41 earnings per share. Integra LifeSciences’s quarterly revenue was up 2.4% compared to the same quarter last year. On average, analysts expect Integra LifeSciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Integra LifeSciences Price Performance

Shares of NASDAQ IART opened at $19.79 on Monday. The company has a quick ratio of 1.95, a current ratio of 3.38 and a debt-to-equity ratio of 1.75. The firm has a 50-day moving average price of $17.39 and a 200 day moving average price of $13.31. Integra LifeSciences has a 52 week low of $8.70 and a 52 week high of $20.26. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of -3.06, a price-to-earnings-growth ratio of 1.37 and a beta of 1.22.

Analysts Set New Price Targets

IART has been the subject of several research analyst reports. Citigroup reaffirmed a “neutral” rating and issued a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a research note on Wednesday, July 8th. Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research report on Thursday, June 18th. BMO Capital Markets began coverage on Integra LifeSciences in a research note on Wednesday, July 8th. They set a “market perform” rating and a $19.00 price target for the company. Wells Fargo & Company boosted their price objective on shares of Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Finally, Truist Financial lifted their target price on shares of Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Integra LifeSciences has an average rating of “Reduce” and a consensus price target of $18.33.

Hedge Funds Weigh In On Integra LifeSciences

A number of large investors have recently modified their holdings of the company. Global Retirement Partners LLC purchased a new stake in shares of Integra LifeSciences during the fourth quarter valued at approximately $25,000. Osaic Holdings Inc. raised its position in shares of Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 1,104 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Integra LifeSciences by 595.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after buying an additional 6,814 shares during the period. Virtu Financial LLC acquired a new stake in Integra LifeSciences in the fourth quarter worth about $124,000. Finally, Amundi lifted its holdings in shares of Integra LifeSciences by 17,193.8% in the second quarter. Amundi now owns 11,068 shares of the life sciences company’s stock valued at $150,000 after buying an additional 11,004 shares during the period. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.